Ocular Therapeutix (OCUL) Total Current Liabilities (2013 - 2026)

Ocular Therapeutix's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $47.7 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 25.73% year-over-year to $47.7 million; the TTM figure through Mar 2026 stood at $47.7 million (up 25.73% YoY), while the FY2025 annual figure was $50.8 million, up 22.86% from the prior year.
• Total Current Liabilities was $47.7 million for Q1 2026 at Ocular Therapeutix, down from $50.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $50.8 million in Q4 2025 to a low of $24.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $35.5 million across 5 years, with a median of $34.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities fell 18.23% in 2024, then soared 56.09% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $31.4 million in 2022, then climbed by 11.15% to $34.9 million in 2023, then gained by 18.51% to $41.4 million in 2024, then grew by 22.86% to $50.8 million in 2025, then declined by 6.15% to $47.7 million in 2026.
• The last three Total Current Liabilities figures came in at $47.7 million (Q1 2026), $50.8 million (Q4 2025), and $49.3 million (Q3 2025), per Business Quant data.